Establishment Labs projects 25%+ growth through 2027, anticipates 2026 free cash flow positive, and reports strong preliminary 2025 revenue.

summarizeSummary

Establishment Labs presented a robust financial outlook at the J.P. Morgan Healthcare Conference, forecasting significant revenue growth and profitability through 2027, alongside strong preliminary 2025 results.

check_boxKey Events

• Strong 2026-2027 Financial Outlook

  The company expects to grow at least 25% in both 2026 and 2027, achieve free cash flow positive in 2026, and meaningful earnings starting in 2027, building on 70% gross margin and positive Adjusted EBITDA in Q3 2025.

• Preliminary 2025 Revenue

  Reported preliminary full-year 2025 revenue between $210.5 million and $211.5 million, representing 27% year-over-year growth. Motiva US revenue in its first year reached $45.4 million to $45.9 million.

• Minimally Invasive Platform Revenue Target

  The Motiva Minimally Invasive Platform is projected to drive at least $30 million in revenue in 2026, with a formal launch in Q1 2026.

• Regulatory Progress

  A PMA supplement for Motiva Implants® primary and revision reconstruction indications was submitted to the FDA in December 2025, potentially doubling the total addressable market.

auto_awesomeAnalysis

This 8-K filing, accompanying a presentation at the J.P. Morgan Healthcare Conference, provides a highly positive and comprehensive update on Establishment Labs' financial performance and strategic direction. The preliminary 2025 revenue figures demonstrate strong growth, particularly in the crucial U.S. market for Motiva. More significantly, the company's forward-looking guidance for 2026 and 2027, projecting at least 25% annual growth, achieving free cash flow positive status in 2026, and meaningful earnings by 2027, signals a clear path to sustained profitability and operational leverage. The progress in the minimally invasive platform and the submission of a PMA supplement for breast reconstruction further highlight the company's innovation pipeline and potential for market expansion. Investors should view this as a strong affirmation of the company's growth trajectory and improving financial health.